Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857100 | 1.00 | SLC18A3 (0.46) | SLC18A3SLC18A2CCR5 | |
| SCHEMBL6851261 | 0.96 | SLC18A3 (0.48) | SLC18A3SLC18A2CCR5 | |
| SCHEMBL10686179 | 0.87 | SLC18A2 (0.54) | SLC18A2 | |
| SCHEMBL11374599 | 0.81 | ALDH1A1 (0.44) | — | |
| SCHEMBL12128577 | 0.81 | MEN1 (0.53) | SLC18A3SLC18A2 | |
| SCHEMBL9906702 | 0.79 | SLC6A2 (0.46) | — | |
| SCHEMBL7254828 | 0.77 | SLC18A3 (0.43) | SLC18A3 | |
| SCHEMBL4339380 | 0.77 | SIGMAR1 (0.54) | — | |
| SCHEMBL12128324 | 0.77 | MEN1 (0.52) | SLC18A2 | |
| SCHEMBL6854749 | 0.76 | SIGMAR1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787563-B2 | ANTIDIARRHEA AGENTS; GASTROINTESTINAL DISORDERS | PFIZER INC. | 2004-09-07 | — | — | US | claimed |
| US-20030139448-A1 | N-(cyclopropylmethyl)azacycloalkanes, compositions containing them and methods of preparation | WARNER-LAMBERT COMPANY | 2003-07-24 | — | — | US | claimed |
| EP-1321461-A1 | N-(Cyclopropylmethyl)-azacycloalkanes, compositions containing them and methods for their preparation | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| US-6787563-B2 | ANTIDIARRHEA AGENTS; GASTROINTESTINAL DISORDERS | PFIZER INC. | 2004-09-07 | — | — | US | disclosed |
| US-20030139448-A1 | N-(cyclopropylmethyl)azacycloalkanes, compositions containing them and methods of preparation | WARNER-LAMBERT COMPANY | 2003-07-24 | — | — | US | disclosed |
| EP-1321461-A1 | N-(Cyclopropylmethyl)-azacycloalkanes, compositions containing them and methods for their preparation | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139448-A1 | N-(cyclopropylmethyl)azacycloalkanes, compositions containing them and methods of preparation | DNMT1, TPMT, AZI2 | SLC18A3 4299/4885SLC18A2 4557/4885CCR5 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.